Valion Bio Responds to U.S. Armed Services Committee’s Call for Nuclear Countermeasures

Valion Bio and the U.S. Armed Services:

Valion Bio, Inc. (NASDAQ: VBIO), previously known as Tivic Health Systems, has recently confirmed a significant initiative by the U.S. House Armed Services Committee aimed at addressing urgent needs related to radiation and nuclear countermeasures (NCMs). This initiative stems from the fiscal year 2027 National Defense Authorization Act (NDAA) processes currently underway in Congress. It presents a critical opportunity for the development and prioritization of medical countermeasures that can both proactively protect and therapeutically treat radiation exposure.

Urgent Need for Radiation/Nuclear Countermeasures

The Armed Services Committee's report specifically directs the Assistant Secretary of Defense for Nuclear Deterrence and Biological Defense Policy to coordinate the development of plans that will prioritize both prophylactic (pre-exposure) and therapeutic (post-exposure) countermeasures for radiation. This directive addresses ongoing concerns about national security and military readiness, emphasizing the necessity for effective medical responses to potential nuclear threats.

Valion Bio's initiative aligns with the Committee's push, illustrating a robust commitment to advancing medical solutions that offer dual benefits: protective mechanisms before exposure and therapeutic interventions after exposure. This comprehensive approach not only enhances the Department of War's (DoW) readiness but also catalyzes advancements in protecting military personnel against emerging nuclear and radiological threats.

Entolimod: A Key Focus

Valion Bio has made significant strides with its lead candidate, Entolimod, designed specifically for managing acute radiation syndrome (ARS). Following the company's recent briefings with senior officials at the Department of War and the Biomedical Advanced Research and Development Authority (BARDA), the potential of Entolimod is gaining prominence in discussions surrounding government funding and prioritization of defense initiatives.

Entolimod is a novel recombinant deletion variant of Salmonella FliC flagellin, carefully engineered to engage Toll-Like Receptor 5 (TLR5). This mechanism activates various biological pathways, leading to protective effects on critical tissues affected by radiation, including hematopoietic and gastrointestinal systems. Clinical evidence suggests that Entolimod offers significant survival benefits as both a radioprotectant and radiomitigant in studies conducted on non-human primates, adhering to the FDA's guidelines under the Animal Rule.

Valion Bio's Commitment and Future Potential

Valion Bio's CEO, Michael Handley, expressed strong support for the Committee's initiative. He noted, "For too long, nuclear/radiation preparedness has relied on agents that can only be used after the damage is done. This acknowledgment of the need for a dual-action countermeasure represents a vital shift in our defense strategy. We are invigorated that our potential product, Entolimod, is being prioritized at the highest levels of the U.S. defense establishment."

The innovative approach adopted by Valion Bio emphasizes the need to protect and prepare against potential nuclear hazards systematically. With government support, the company aims to enhance its drug pipeline through disciplined research, development, and manufacturing, notably utilizing its subsidiary, Velocity Bioworks. This full-service contract development and manufacturing organization (CDMO) offers critical capabilities to accelerate Valion Bio's initiatives while optimizing costs and ensuring supply chain reliability.

Looking Forward

The focus on radiation and nuclear countermeasures marks an essential progression in national defense and public health. Valion Bio remains at the forefront of this transformative landscape, advocating for a balanced approach that combines proactive defense through Entolimod and ongoing development strategies. As discussions continue within Congress and among key defense authorities, the future of Valion Bio could significantly shape the preparedness and health of military personnel in the United States and beyond.

For more information about Valion Bio and its initiatives, please visit Valion Bio's official website.